Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
COX Inhibitor
Ibuprofen Impurity K is a chemical impurity associated with Ibuprofen, a well-known nonsteroidal anti-inflammatory drug (NSAID) that functions as a cyclooxygenase (COX) inhibitor. It selectively inhibits COX-1 with an IC50 of 13 μM and COX-2 with an IC50 of 370 μM, contributing to its anti-inflammatory effects. This compound is relevant for studies focused on the metabolism and safety of Ibuprofen, as well as for research into the pharmacological profiles of COX inhibitors. -
COX Inhibitor
Thiazolinobutazone is a selective cyclooxygenase (COX) inhibitor that exhibits anti-inflammatory properties. This compound is recognized for its reduced toxicity compared to Phenylbutazone, making it a safer alternative in pharmacological research. Thiazolinobutazone is primarily utilized in the investigation of various immunological diseases, providing insights into COX-related pathways and inflammation mechanisms. -
COX Inhibitor
LY150310 free base is a potent COX inhibitor that effectively inhibits thromboxane synthase and cyclooxygenase, as well as thrombin activation. This compound demonstrates a dose-dependent ability to inhibit spontaneous lung metastasis, making it valuable for research applications aimed at understanding metastatic processes and developing anti-cancer therapies. -
COX-2 Inhibitor
COX-2-IN-12 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 19.98 μM, demonstrating potent anti-inflammatory properties. This compound is suitable for various biological research applications related to inflammation and pain management. In vivo acute toxicity studies indicate a favorable safety profile for COX-2-IN-12, supporting its potential for therapeutic exploration. -
COX-1 Inhibitor
(+)-Catechin pentaacetate serves as a precursor for the synthesis of (+)-catechin, a natural compound with herbicidal and antimicrobial properties. This compound functions as a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 1.4 μM. Its ability to modulate COX-1 activity makes it valuable for research in inflammation and pain response pathways. -
COX-2 Inhibitor
COX-2-IN-23 is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting IC50 values of 0.28 μM for COX-2 and 20.14 μM for COX-1. This compound demonstrates significant anti-inflammatory activity while maintaining a low ulcerogenic profile, making it suitable for research applications focused on inflammation and pain modulation. Its selectivity and efficacy position it as a valuable tool in the study of inflammatory pathways. -
COX Inhibitor
COX-2-IN-50 is a highly soluble COX-2 inhibitor, exhibiting notable analgesic activity. With a water solubility of 20.3 mg/mL, it surpasses its precursor compound, PC407, which has a solubility of 1.6 μg/mL. This compound demonstrates excellent biocompatibility, making it suitable for the formulation of injectable dosage forms. COX-2-IN-50 has shown significant analgesic effects in vivo, indicating its potential in pain management research and therapeutic applications. -
COX Inhibitor
Diclofenac deanol is a potent cyclooxygenase (COX) inhibitor, particularly exhibiting enhanced selectivity for COX-2 over COX-1. This compound possesses anti-inflammatory, analgesic, and antipyretic properties, making it valuable in pain management and inflammation-related research. Its superior water solubility compared to traditional diflunisal salts facilitates its application in various biological assays and medical research, expanding its potential therapeutic uses. -
COX-2 Inhibitor
COX-2-IN-20 is a selective COX-2 inhibitor with a measured IC50 of 17.9 nM. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research in inflammation and pain management. Its oral bioavailability allows for convenient administration in various studies aimed at understanding COX-2's role in inflammatory diseases. -
COX Inhibitor
Flunixin is a cyclooxygenase (COX) inhibitor that exhibits IC50 values of 0.55 μM for COX-1 and 3.24 μM for COX-2. It is known for its anti-inflammatory properties, making it valuable in studies aimed at understanding inflammatory pathways. Flunixin is commonly utilized in research focused on pain management and related therapeutic applications. -
COX-2 Inhibitor
COX-2-IN-22 is a selective inhibitor of Cyclooxygenase-2 (COX-2) with an IC50 of 8.6 µM. In addition to its primary activity, COX-2-IN-22 also exhibits inhibitory effects on Acetylcholinesterase (AChE), Butyrylcholinesterase (BChE), β-Secretase, Lipoxygenase-5 (LOX-5), and DPPH, with IC50 values of 2.8 µM, 6.3 µM, 15.3 µM, 13.9 µM, and 6.8 µM, respectively. This compound is capable of crossing the blood-brain barrier, making it a valuable tool for research in neuroinflammatory and neurodegenerative disease models. -
COX Inhibitor
2-Hydroxy Ibuprofen is a metabolic derivative of Ibuprofen, functioning primarily as a cyclooxygenase (COX) inhibitor. It demonstrates significant anti-inflammatory activity, targeting COX-1 and COX-2 enzymes with inhibitory concentrations (IC50) of 13 μM and 370 μM, respectively. This compound is valuable for studying the mechanisms of inflammation and pain in various research applications, particularly in pharmacology and toxicology. -
COX-2 Inhibitor
Etoricoxib hydrochloride is a selective COX-2 inhibitor that effectively reduces inflammation and alleviates pain by blocking the conversion of arachidonic acid to prostaglandins. This compound is primarily utilized in research related to osteoarthritis and demonstrates significant anti-inflammatory properties. Additionally, etoricoxib hydrochloride has been shown to promote bone remodeling through enhanced alkaline phosphatase activity. Its formulation, developed using emulsion solvent evaporation technology, ensures good cell compatibility for various biological applications. -
COX-2 Inhibitor
Indomethacin heptyl ester is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 0.04 μM. This compound demonstrates significant anti-inflammatory activity, making it valuable for studying inflammatory processes and discovering potential therapeutic interventions in diseases characterized by COX-2 overexpression. Its specificity for COX-2 provides insights into the mechanism of action and the development of novel anti-inflammatory agents. -
COX Inhibitor
Indobufen sodium is a reversible inhibitor of cyclooxygenase (COX) activity, primarily targeting platelet aggregation. By suppressing the synthesis of thromboxane A2 (TxA2), it effectively modulates platelet function. Additionally, Indobufen sodium down-regulates the expression of tissue factor (TF) in monocytes, making it a valuable tool for research involving cardiovascular and inflammatory processes. -
COX-2/Aromatase Inhibitor
COX-2/Aromatase-IN-2 is a potent dual inhibitor targeting cyclooxygenase-2 (COX-2) and aromatase. It effectively suppresses inflammation and inhibits cell proliferation in breast cancer models, demonstrating significant anti-cancer and anti-inflammatory activities. Proven efficacy in the MCF-7 breast cancer cell line and carrageenan-induced rat paw edema model makes COX-2/Aromatase-IN-2 a valuable tool for researching inflammation and breast cancer pathways. -
5-LOX/COX-1 Inhibitor
Atractylochromene is a dual inhibitor targeting 5-lipoxygenase (5-LOX) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.6 μM and 3.3 μM, respectively. This compound serves as a valuable tool in research related to inflammatory pathways and can facilitate the study of related conditions influenced by leukotrienes and prostaglandins. Its inhibitory effects position Atractylochromene as a potential candidate for therapeutic exploration in inflammatory diseases. -
XO/COX/LOX Inhibitor
XO/COX/LOX-IN-1 is a potent inhibitor of xanthine oxidase, cyclooxygenases, and lipoxygenases. This compound exhibits significant anti-inflammatory activity, making it valuable for research in inflammation, cancer, and metabolic diseases. Its multifaceted inhibition profile positions XO/COX/LOX-IN-1 as a critical tool for exploring pathways involved in these pathological conditions. -
COX Inhibitor
Axinelline A is a potent cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 2.22 μM for COX-2 and 8.89 μM for COX-1. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and potential therapeutic interventions. Axinelline A is suitable for studies focused on the modulation of COX enzymes and the inflammatory response. -
COX-2 Inhibitor
DRF-4848 is a selective inhibitor of cyclooxygenase-2 (COX-2), a key enzyme involved in the inflammatory response. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for studying inflammation-related pathways and diseases. Researchers can utilize DRF-4848 to investigate its effects on pain management and the modulation of inflammatory processes in various biological contexts. -
COX-2 Inhibitor
COX-2-IN-26 is a selective and orally active inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 0.067 µM, demonstrating its potency. This compound exhibits anti-inflammatory properties, making it a valuable tool for research in inflammation-related studies. Additionally, COX-2-IN-26 is noted for its favorable gastrointestinal safety profile, supporting its potential application in therapeutic development. -
COX-2 Inhibitor
Anti-inflammatory agent 56 is a selective COX-2 inhibitor with an IC50 of 0.54 μM. It demonstrates significant anti-inflammatory and antioxidant properties, effectively reducing oxidative stress-induced cell death. By inhibiting key targets such as Keap1, COX-2, and iNOS, this compound mitigates neuroinflammation and oxidative stress. Furthermore, it exhibits low acute toxicity in murine models, with an LD50 of 1000 mg/kg, making it a valuable tool for research in inflammation and neuroprotection. -
COX-2/LOX Inhibitor
COX-2/5-LOX-IN-4 is a potent dual inhibitor targeting both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), with IC50 values of 0.05 μM and 0.003 μM, respectively. By disrupting the arachidonic acid metabolism pathway, this compound effectively decreases the synthesis of prostaglandins and leukotrienes, leading to reduced inflammatory responses. In vivo studies using a rat ear edema model demonstrate its substantial anti-inflammatory activity, with intravenous doses resulting in up to 44% reduction in edema. COX-2/5-LOX-IN-4 is an important tool for investigating the mechanisms underlying inflammatory diseases. -
COX Inhibitor
N-(4-acetamidophenyl)-indomethacin amide is a selective reversible inhibitor of cyclooxygenase-2 (COX-2). It demonstrates potent inhibitory activity against human recombinant and ovine COX-2, with IC50 values of 0.12 μM and 0.625 μM, respectively, while showing significantly lower potency against COX-1 isoforms. This compound is valuable for research applications focused on inflammation, pain management, and the role of COX-2 in various pathological conditions. -
FAAH/COX Inhibitor
Carpro-AM1 is a dual-acting inhibitor targeting fatty acid amide hydrolase (FAAH) and selectively inhibiting cyclooxygenase (COX) enzymes. This compound exhibits an IC50 value of 94 nM for FAAH, demonstrating significant biological activity in regulating endocannabinoid signaling. Carpro-AM1 is suited for research applications focusing on pain management, inflammation, and the modulation of the endocannabinoid system. -
COX-2 Inhibitor
COX-2-IN-33 is a selective COX-2 inhibitor with an IC50 of 45.5 nM, designed for research into inflammatory pathways. This compound demonstrates significant inhibition of pro-inflammatory cytokine production in vivo, indicating its potential as an anti-inflammatory agent while maintaining gastric safety. It is particularly useful for studies focused on chronic inflammation and pain management. -
COX Inhibitor
4'-Aarboxylic acid imrecoxib is a metabolite of Imrecoxib, targeting the cyclooxygenase-2 (COX-2) enzyme. It exhibits anti-inflammatory properties through the inhibition of COX-2, making it valuable for research in pain management and inflammatory disorders. This compound can be utilized in studies focused on the modulation of prostaglandin synthesis. -
COX Inhibitor
Eltenac is a non-steroidal anti-inflammatory drug (NSAID) that acts as a cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood. Its potent inhibitory activity against COX enzymes makes it valuable in studying inflammatory pathways and evaluating potential therapeutic applications related to pain and inflammation management. Researchers can utilize Eltenac in various experimental settings to explore the role of COX in disease processes. -
COX Inhibitor
Butanixin is a cyclooxygenase (COX) inhibitor that demonstrates significant anti-inflammatory and analgesic properties through the reduction of prostaglandin synthesis. This compound is primarily utilized in the research of musculoskeletal disorders, providing valuable insights into therapeutic mechanisms targeting inflammation and pain management. Its effectiveness in modulating COX activity makes it a relevant tool for investigating inflammatory pathways. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-7 is a selective dual inhibitor targeting cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX) with IC50 values of 0.022 and 1.19 μM, respectively. It also demonstrates inhibition of COX-1 with an IC50 of 28.081 μM. This compound exhibits low cytotoxicity in human colorectal cancer cell lines (HT-29 and HCT116) with IC50 values exceeding 100 μM, and shows a non-ulcerogenic profile. COX-2/15-LOX-IN-7 is valuable for cancer research applications, facilitating the study of inflammatory pathways and therapeutic interventions. -
COX-1 Inhibitor
Ethoxycoronarin D is a labdane diterpene that functions as a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 3.8 µM. This compound demonstrates significant anti-inflammatory activity and has potential applications in research related to pain management and various inflammatory conditions. Its selective inhibition of COX-1 may provide insights into the mechanisms underlying inflammation and pain pathways. -
COX/5-LOX Inhibitor
CI-986 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), effectively preventing coronary vasoconstriction and the excessive production of leukotrienes, including LTB4 and LTC4. This compound exhibits notable anti-inflammatory and analgesic properties, making it a valuable tool for research into inflammation and cardiovascular diseases, including conditions like arthritis. CI-986's unique mechanism positions it as an important reagent in studies focused on the modulation of inflammatory pathways and vascular health. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-1 is a dual inhibitor targeting cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), represented as a benzothiophen-2-yl pyrazole carboxylic acid derivative. This compound exhibits significant analgesic and anti-inflammatory properties, demonstrating enhanced efficacy compared to traditional nonsteroidal anti-inflammatory drugs. COX-2/5-LOX-IN-1 displays potent inhibition of COX-1, COX-2, and 5-LOX, with IC50 values of 12.13, 0.4, and 4.96 μM, respectively, making it a valuable tool for research in pain and inflammation pathways. -
COX-2 Inhibitor
PYZ18 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 7.07 μM. This compound demonstrates significant anti-inflammatory properties, making it a valuable tool in the study of inflammatory diseases. PYZ18 is suitable for research applications exploring COX-2 inhibition and its potential therapeutic effects. -
NF-κB/COX Inhibitor
Methoxycoronarin D is a potent inhibitor of NF-κB, demonstrating an IC50 value of 7.3 μM. Additionally, it selectively inhibits cyclooxygenase-1 (COX-1), with an IC50 value of 0.9 μM. This compound is relevant for research applications focused on inflammation and cancer due to its ability to modulate critical signaling pathways. -
COX-2/5-LOX Inhibitor
Speranskoside is a dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase-15 (5-LOX), exhibiting an IC50 of 2.62 μg/mL for COX-2 and 5.51 μg/mL for 5-LOX. This compound demonstrates significant anti-inflammatory activity, making it valuable for the investigation of gastric ulcers and related disorders. Its unique mechanism of action provides a foundational tool for research into inflammatory pathways and therapeutic interventions. -
COX Inhibitor
11(R)-HEDE is a selective inhibitor of cyclooxygenase (COX), produced through the lipoxygenase-type reaction of 11Z,14Z-eicosadienoic acid. It is utilized in research studies to assess COX activity by measuring the absorbance of conjugated dienes spectrophotometrically. This compound is valuable for investigating the role of COX in various biological processes and disease models, contributing to the understanding of inflammatory pathways and potential therapeutic applications. -
COX-2 Inhibitor
COX-2-IN-24 is an orally active inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 0.17 μM. This compound exhibits significant anti-inflammatory properties while demonstrating low ulcerogenic activities, making it suitable for research on inflammatory diseases and pain management. Its selective inhibition of COX-2 provides valuable insights into the mechanisms of inflammation and the development of therapeutic strategies. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-3 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX), exhibiting IC50 values of 45.73 µM for COX-1, 5.45 µM for COX-2, and 4.33 µM for 5-LOX. This compound is valuable for studying inflammatory diseases, as it effectively modulates the associated biochemical pathways. Its dual inhibition may provide insights into the complex roles of COX-2 and 5-LOX in mediating inflammatory responses. -
COX Inhibitor
Timegadine hydrochloride is a selective inhibitor of cyclooxygenase (COX) and lipoxygenase, playing a significant role in inflammatory processes. It demonstrates potent COX inhibition in washed rabbit platelets and rat brain, with IC50 values of 5 nM and 20 μM, respectively. Additionally, Timegadine hydrochloride effectively inhibits lipoxygenase in equine and washed rabbit platelets with an IC50 of 100 μM. This compound is of interest for research applications focusing on anti-arthritis activity and other inflammatory conditions. -
COX-2 Inhibitor
RS-57067 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an inhibition constant (Ki) of 16.9 μM. By effectively reducing the production of prostaglandins, including PGE2, it mitigates inflammatory responses. This compound is suitable for research applications focused on inflammatory and immune-related diseases. -
COX-2 Inhibitor
BMS-347070 is a selective inhibitor of cyclooxygenase-2 (COX-2), primarily involved in inflammatory processes. This compound exhibits significant anti-inflammatory activity and is valuable in research aimed at understanding COX-2’s role in various diseases. Additionally, BMS-347070 can be utilized in studies on Pluronic®-based nano-crystalline drug-polymer solid dispersions for improved drug delivery applications. -
COX Inhibitor
Lobuprofen is a potent COX inhibitor that selectively targets cyclooxygenases (COX-1 and COX-2). It demonstrates significant anti-inflammatory and analgesic effects, making it suitable for research into neurological disorders and related pathologies. This compound can help elucidate the role of inflammation in the progression of neurological diseases and facilitate the development of therapeutic strategies. -
COX-2 Inhibitor
COX-2-IN-38 is a potent inhibitor of cyclooxygenase-2 (COX-2), demonstrating an IC50 value of 79.4 nM. This compound effectively modulates inflammatory processes by selectively blocking COX-2 activity, making it a valuable tool for research focused on inflammation and pain management. Its application in various biological assays can aid in the investigation of COX-2-related pathways and the development of anti-inflammatory therapies. -
COX-2 Inhibitor
Ataquimast free base is a selective COX-2 inhibitor that effectively reduces the production of leukotrienes, tumor necrosis factor-alpha (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is primarily utilized in research focused on advanced estrogen receptor-positive breast cancer, making it valuable for studies examining the inflammatory response and tumor progression in this context. -
COX Inhibitor
4',5-Dihydroxy Diclofenac-13C6 is a deuterated derivative of Diclofenac, functioning primarily as a cyclooxygenase (COX) inhibitor. This compound exhibits significant anti-inflammatory activity, making it useful for studying the mechanisms of inflammation and pain management. Its isotopic labeling allows for advanced analytical techniques in pharmacokinetic studies and metabolic research. -
COX-2 Inhibitor
Indomethacin N-octyl amide is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating an IC50 of 40 nM. This compound exhibits greater than 1000-fold selectivity over COX-1, with an IC50 of 66 µM. Its potent COX-2 inhibitory activity makes Indomethacin N-octyl amide a valuable tool for research into inflammation and pain pathways. -
COX Inhibitor
AL-8417 ((2R)-AL-5898) is a potent inhibitor of Cyclooxygenase (COX), exhibiting an IC50 of 120 μM. This compound is significant in modulating inflammatory responses, making it a valuable tool for research into pain relief and inflammation management. Its application in experimental settings can further elucidate the role of COX in various biological processes and disease states. -
COX-2 Inhibitor
N-Caffeoyl serotonin is a selective COX-2 inhibitor, characterized by IC50 and Kᵢ values of 42.5 μM and 65.5 μM, respectively. This compound exhibits minimal inhibitory activity against BACE1, with an IC50 greater than 400 μM, and demonstrates free radical scavenging properties. N-Caffeoyl serotonin is pertinent for research in allergic diseases as well as Alzheimer's disease, providing a valuable tool for investigating inflammatory pathways and neurodegeneration. -
COX-2 Inhibitor
Harmaline analog is a selective inhibitor of cyclooxygenase-2 (COX-2) demonstrating an IC50 of 0.145 μM. This compound is useful for studying the COX-2 enzyme's role in inflammatory processes and pain modulation. Its application includes research on anti-inflammatory therapies and the development of novel analgesics.
